A carregar...
Publicação
I2 therapeutics: financial modeling and business plan creation for a disruptive cancer drug improvement biotech startup
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 3.18 MB | Adobe PDF |
Orientador(es)
Resumo(s)
I2 Therapeutics aims at developing its proprietary technology in house and license the use of that technology to big pharma companies. On accordance to that business model, I2 Therapeutics expects to raise $ 1 million in seed funding now and a $ 25 million in series A funding by 2024. The RNPV of I2 Therapeutics currently is around $ 33 million. I2 Therapeutics is exploiting a legal framework that allows it to reduce the time to market. I2 Therapeutics aims at raising the seed funding through VC funds to capture their expertise. Series A fundraising is planned to be a hybrid between VC funds and a pharma company equity investment. This would allow I2 Therapeutics to attract a potential licensee whilst reducing risk and aligning interests for both parties.
Descrição
Palavras-chave
Entrepreneurship Venture capital Science Leadership Innovation R&D Entrepreneurial finance